Phase 3 Start

BZYR: Phase3_Start: A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

Name: Phase3_Start: A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma
Start: 2027-06-01
End: 2027-06-01

June 1, 2027. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: June 1, 2027
Company: BURZYNSKI RESEARCH INSTITUTE INC (BZYR)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Start

Phase3_Start: A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma

June 1, 2027

BZYR overview →

Company: BURZYNSKI RESEARCH INSTITUTE INC (BZYR)